key: cord-0803186-veku7a4q authors: Abusrewil, Suleiman; Algeer, Abdulrahman; Aljifri, Alanoud; Al Slail, Fatima; Andrew, Melissa K.; Awad Tag Eldin, Mohamed; Al Awaidy, Salah; Ben Alaya, Nissaf; Ben Khelil, Jalila; Dbaibo, Ghassan; Derrar, Fawzi; Elahmer, Omar; Ghosn, Nada; Gabriel, Guelsah; Grasso, Cindy; Hassan, Mohamed; Hirve, Siddhivinayak; Mirza, Yusuf Kamal; Rateb, Yousef Moh'd; Nourlil, Jalal; Nunes, Marta C.; Omaima, Idris; Malande, Oliver Ombeva; Saadatian‐Elahi, Mitra; Sanchez‐Picot, Valentina; Sk. Mamunur Rahman, Malik; Tarraf, Hesham; Walaza, Sibongile title: Influenza surveillance in Middle East, North, East and South Africa: Report of the 8th MENA Influenza Stakeholders Network date: 2019-02-22 journal: Influenza Other Respir Viruses DOI: 10.1111/irv.12628 sha: e5c0ca285de27831edf5b0306750cfa3f69eba8e doc_id: 803186 cord_uid: veku7a4q The Middle‐East and Africa Influenza Surveillance Network (MENA‐ISN), established in 2014, includes 15 countries at present. Country representatives presented their influenza surveillance programmes, vaccine coverage and influenza control actions achieved, and provided a list of country surveillance/control objectives for the upcoming 3 years. This report details the current situation of influenza surveillance and action plans to move forward in MENA‐ISN countries. Data were presented at the 8th MENA‐ISN meeting, organized by the Mérieux Foundation that was held on 10‐11 April 2018 in Cairo, Egypt. The meeting included MENA‐ISN representatives from 12 countries (Algeria, Egypt, Jordan, Kenya, Lebanon, Libya, Morocco, Pakistan, Saudi Arabia, South Africa, Tunisia and United Arab Emirates) and experts from the Canadian Centre for Vaccinology, and the World Health Organization. Meeting participants concluded that influenza remains a significant threat especially in high‐risk groups (children under‐5, elderly, pregnant women and immunosuppressed individuals) in the MENA‐ISN region. Additional funding and planning are required by member countries to contain this threat. Future meetings will need to focus on creative and innovative ways to inform policy and initiatives for vaccination, surveillance and management of influenza‐related morbidity and mortality especially among the most vulnerable groups of the population. gion. Additional funding and planning are required by member countries to contain this threat. Future meetings will need to focus on creative and innovative ways to inform policy and initiatives for vaccination, surveillance and management of influenza-related morbidity and mortality especially among the most vulnerable groups of the population. The MENA-ISN roadmap is now available to help achieving the network's goals. Emerging infectious diseases are a major public health problem in the EMR region. Besides, more than half of the 22 countries of the EMR are affected by acute or protracted complex emergencies. Elderly individuals are also at high risk of influenza-related hospitalization and death. 6, 7 Frailty is defined as "a state of increased vulnerability to poor resolution of homoeostasis after a stressor event", which increases the risk of adverse outcomes, 8 found to reduce hospital admission with respiratory illness [16] [17] [18] and to be cost-saving. 19, 20 Finally, a recombinant influenza vaccine has been shown to provide a better protection in older adults than the standard quadrivalent, inactivated influenza vaccine. 21 At present, the availability of these newer vaccine products is limited in many settings, and where available, they may be cost-prohibitive. With this in mind, implementing a realistic vaccination strategy with available product in order to improve influenza vaccine coverage should be considered as the first-line strategy with whatever influenza vaccine available in a given country. In summary, despite enhanced influenza surveillance systems, a higher number of NICs that actively perform influenza virus typing and more available information on influenza burden in the region, the current situation is not satisfactory. Key challenges for the future are sustainability, good quality data and more privateacademic collaborations under a common scientific umbrella. A unified group of committed national experts, that is MENA-ISN with joint multisectoral and multidisciplinary efforts, will help to get further than individual efforts. The network can be the active advocate for acceptance of vaccination by HCPs and the public, by bringing key local stockholders together, explaining benefits of seasonal influenza vaccination and addressing misinformation. Dissemination of surveillance and disease burden data through publications and effective communication tools will help to push health authorities in favour of official recommendations for influenza vaccination. This work was supported by Fondation Mérieux and an unrestricted grant from Sanofi Pasteur. The authors declare no conflict of interest to report. Mitra Saadatian-Elahi https://orcid.org/0000-0003-1265-8806 Sibongile Walaza https://orcid.org/0000-0001-7588-2480 Zaraket H; List of authors is in alphabetical order. Influenza vaccination situation in Middle-East and North Africa countries: Report of the 7th MENA Influenza Stakeholders Network (MENA-ISN) World Health Organization. National Influenza Centres, Eastern Mediterranean Region of WHO Fourth EMARIS meeting and first scientific conference on acute respiratory infections in the Eastern Mediterranean Region Poster and Oral Presentation Abstracts Efficacy of maternal influenza vaccination against all-cause lower respiratory tract infection hospitalizations in young infants: results from a randomized controlled trial Modelling estimates of age-specific influenza-related hospitalisation and mortality in the United Kingdom Influenza-related hospitalisation and death in Australians aged 50 years and older Frailty in elderly people Serious Outcomes Surveillance Network of the Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) and the Toronto Invasive Bacterial Diseases Network (TIBDN). The importance of frailty in the assessment of influenza vaccine effectiveness against influenza-related hospitalization in elderly people Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans A global clinical measure of fitness and frailty in elderly people Vaccinations against respiratory tract infections at Hajj A case-control study of influenza vaccine effectiveness among Malaysian pilgrims attending the Haj in Saudi Arabia Immunosenescence: influenza vaccination and the elderly Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial Efficacy and safety of highdose influenza vaccine in elderly adults: a systematic review and meta-analysis Efficacy of highdose versus standard-dose influenza vaccine in older adults High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standarddose inactivated influenza vaccine in Canadian seniors Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial PSC12 Study Team. Efficacy of recombinant influenza vaccine in adults 50 years of age or older Report of the 8th MENA Influenza Stakeholders Network